Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program

Core Insights - Precision BioSciences has received two Notices of Allowance from the U.S. Patent and Trademark Office for its PBGENE-HBV program, which focuses on gene editing therapies for Hepatitis B [1] - The first patent application covers engineered meganucleases targeting the Hepatitis B virus genome, while the second application pertains to polypeptide linkers used in these engineered nucleases [1] - The patents, once granted, are expected to provide composition-of-matter protection for the PBGENE-HBV ARCUS nuclease until at least November 2044, enhancing the company's intellectual property portfolio [1] Company Overview - Precision BioSciences is a clinical stage gene editing company utilizing its proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet needs [1] - The PBGENE-HBV program is currently in a global first-in-human clinical trial aimed at providing a potentially curative treatment for chronic Hepatitis B infection [1] - The program has received Fast Track designation from the FDA, indicating its potential significance in addressing chronic Hepatitis B [1] Patent Details - The first Notice of Allowance relates to U.S. Patent Application No. 19/347,136, which includes claims for the ARCUS nuclease used in PBGENE-HBV [1] - The second Notice of Allowance pertains to U.S. Patent Application No. 19/273,982, covering any polypeptide that includes a novel, shortened polypeptide linker developed by Precision [1] - Both patents are expected to provide overlapping coverage across multiple patent families, strengthening the company's position in the market [1]